Transport
Baxter County Regional Hospital, INC
Baxter County Regional Hospital, INC was paid $15.20M by Medicaid between Jan 2018 and Dec 2024, across 320 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 5.1% of everything it billed.
33Billing provider infoBAXTER COUNTY REGIONAL HOSPITAL, INC
MOUNTAIN HOME, AR 72653
MOUNTAIN HOME, AR 72653
33aNPI1881788933assigned 10/03/2006
33bProvider typeAmbulance
28Total paid$15.20M
24GClaims701,694
24DCodes billed320
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in Arkansas
Rank by total paid#2 of 21
Median peer was paid$734K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HENRY, DEBRA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 86,763 | $1.63M | |
| 2019 | 96,403 | $2.13M | |
| 2020 | 93,173 | $1.93M | |
| 2021 | 102,470 | $2.19M | |
| 2022 | 117,980 | $2.64M | |
| 2023 | 110,848 | $2.65M | |
| 2024incomplete | 94,057 | $2.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.1% | 14,783 | 3,942 | $773K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.9% | 4,230 | 3,879 | $586K |
| 62323 | 3.4% | 3,054 | 2,736 | $510K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 3.1% | 1,943 | 1,830 | $468K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 3,229 | 2,938 | $467K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.0% | 4,151 | 1,906 | $457K |
| 64635 | 2.6% | 1,752 | 1,538 | $398K | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 4,041 | 3,641 | $390K |
| 59025 | Fetal non-stress test | 2.5% | 2,255 | 1,609 | $380K |
| 80305 | 2.3% | 28,969 | 25,729 | $356K | |
| 80053 | Comprehensive metabolic panel | 2.3% | 28,559 | 24,140 | $354K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.2% | 24,510 | 20,468 | $329K |
308 more codes
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.1% | 1,695 | $325K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.1% | 6,077 | $319K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.0% | 3,053 | $305K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 1.9% | 23,225 | $294K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 45,351 | $290K |
| A0425 | Ground mileage, per statute mile | 1.8% | 5,451 | $277K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 20,813 | $270K |
| 64493 | 1.3% | 939 | $203K | |
| 72141 | 1.3% | 806 | $200K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 3,216 | $167K |
| 62321 | 1.1% | 993 | $166K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 1,422 | $161K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,023 | $151K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,742 | $146K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,427 | $146K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,132 | $145K |
| 80361 | <1% | 3,970 | $140K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,387 | $135K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,315 | $131K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,800 | $125K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,800 | $124K |
| 64636 | <1% | 852 | $119K | |
| 71250 | <1% | 1,435 | $118K | |
| 87634 | <1% | 1,459 | $117K | |
| 80050 | General health panel | <1% | 2,476 | $116K |
| 80348 | <1% | 4,130 | $115K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,645 | $113K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,646 | $112K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,643 | $111K |
| 97162 | <1% | 1,159 | $107K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,703 | $105K |
| 80061 | Lipid panel | <1% | 9,113 | $103K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,583 | $103K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,522 | $99K |
| 86901 | <1% | 4,428 | $99K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,635 | $92K |
| 84484 | <1% | 7,928 | $91K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 376 | $90K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,640 | $81K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,167 | $80K |
| 74022 | <1% | 3,325 | $78K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,978 | $78K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,350 | $77K |
| 99283 | Emergency room visit (moderate) | <1% | 3,588 | $74K |
| 83880 | <1% | 2,761 | $73K | |
| 86140 | <1% | 9,262 | $71K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,245 | $71K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,970 | $68K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 401 | $67K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,429 | $67K |
| 83605 | <1% | 5,606 | $66K | |
| 80346 | <1% | 2,367 | $66K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 2,875 | $64K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 214 | $63K |
| 82803 | <1% | 2,259 | $56K | |
| 84145 | <1% | 2,732 | $54K | |
| 97597 | <1% | 1,661 | $49K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 149 | $47K |
| 87040 | <1% | 3,547 | $46K | |
| 99284 | Emergency room visit (serious) | <1% | 4,722 | $46K |
| 87077 | <1% | 4,485 | $46K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,201 | $46K |
| 72100 | <1% | 1,711 | $44K | |
| 74178 | <1% | 350 | $41K | |
| 81025 | <1% | 4,872 | $41K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 120 | $41K |
| C1769 | Guide wire | <1% | 702 | $40K |
| 72131 | <1% | 351 | $40K | |
| 85027 | <1% | 5,782 | $40K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,210 | $39K |
| 76642 | <1% | 1,408 | $38K | |
| 93017 | <1% | 1,909 | $37K | |
| 83690 | <1% | 4,909 | $36K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,020 | $34K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,553 | $33K |
| 82607 | <1% | 2,010 | $32K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 336 | $31K |
| 80320 | <1% | 1,681 | $30K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,914 | $30K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,164 | $30K |
| 51701 | <1% | 162 | $30K | |
| 87070 | <1% | 2,268 | $30K | |
| 72040 | <1% | 1,168 | $29K | |
| 99285 | Emergency room visit (most serious) | <1% | 2,839 | $28K |
| 80365 | <1% | 1,097 | $28K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,737 | $28K |
| 95886 | <1% | 474 | $28K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,692 | $28K |
| 86850 | <1% | 4,372 | $28K | |
| 86900 | <1% | 4,438 | $27K | |
| 84439 | <1% | 2,439 | $27K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,409 | $27K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 218 | $27K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 124 | $26K |
| 80076 | <1% | 3,316 | $25K | |
| 81001 | <1% | 8,721 | $24K | |
| 73630 | <1% | 848 | $24K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,428 | $23K |
| 87186 | <1% | 4,484 | $23K | |
| 86003 | <1% | 113 | $22K | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 358 | $21K |
| 85730 | <1% | 4,494 | $21K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 125 | $21K |
| 87075 | <1% | 1,572 | $21K | |
| 73562 | <1% | 546 | $20K | |
| 83735 | <1% | 3,691 | $20K | |
| 73030 | <1% | 821 | $20K | |
| 80324 | <1% | 991 | $20K | |
| 77066 | Tomosynthesis, mammo | <1% | 250 | $20K |
| 82948 | <1% | 3,850 | $19K | |
| 86803 | <1% | 1,099 | $19K | |
| 82728 | <1% | 1,564 | $19K | |
| 85610 | <1% | 6,107 | $18K | |
| 81003 | <1% | 8,066 | $18K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 51 | $18K |
| 97001 | <1% | 374 | $18K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 109 | $17K |
| 74018 | <1% | 854 | $17K | |
| 80355 | <1% | 940 | $16K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,483 | $16K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 815 | $15K |
| 73130 | <1% | 557 | $15K | |
| 73610 | <1% | 723 | $14K | |
| 86762 | <1% | 784 | $14K | |
| 0002A | <1% | 539 | $14K | |
| 80349 | <1% | 566 | $13K | |
| 88304 | <1% | 587 | $12K | |
| 93226 | <1% | 196 | $12K | |
| 84702 | <1% | 1,054 | $12K | |
| 86787 | <1% | 738 | $12K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 432 | $11K |
| 86592 | <1% | 2,168 | $11K | |
| 73110 | <1% | 397 | $10K | |
| 82565 | <1% | 776 | $10K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 208 | $9K |
| 84481 | <1% | 390 | $9K | |
| 95911 | <1% | 93 | $9K | |
| 73502 | <1% | 387 | $9K | |
| 80074 | <1% | 210 | $9K | |
| 82150 | <1% | 1,174 | $9K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 68 | $8K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 168 | $8K |
| 85379 | <1% | 883 | $8K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,410 | $8K |
| 12001 | <1% | 40 | $7K | |
| 87522 | Neg quan hep c or qual rna | <1% | 301 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,884 | $7K |
| 93458 | <1% | 63 | $7K | |
| 93225 | <1% | 186 | $7K | |
| 83540 | <1% | 1,245 | $7K | |
| 0001A | <1% | 465 | $7K | |
| 82746 | <1% | 401 | $7K | |
| 87660 | <1% | 251 | $6K | |
| 87481 | <1% | 147 | $6K | |
| 87340 | <1% | 508 | $6K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 25 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,836 | $6K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 20 | $5K |
| 64494 | <1% | 272 | $5K | |
| 84100 | <1% | 1,769 | $5K | |
| 71020 | <1% | 423 | $5K | |
| 87185 | <1% | 1,337 | $5K | |
| 84403 | <1% | 185 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 107 | $5K |
| 76770 | <1% | 165 | $5K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 837 | $5K |
| 77065 | Tomosynthesis, mammo | <1% | 127 | $5K |
| 85652 | <1% | 2,147 | $5K | |
| 82947 | <1% | 819 | $5K | |
| 87400 | <1% | 414 | $5K | |
| 64495 | <1% | 244 | $5K | |
| 82962 | <1% | 1,028 | $4K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 31 | $4K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,106 | $4K |
| 71271 | <1% | 85 | $4K | |
| 42830 | <1% | 19 | $4K | |
| 96367 | <1% | 73 | $4K | |
| 82248 | <1% | 559 | $4K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 72 | $4K |
| 70486 | <1% | 24 | $4K | |
| 77080 | <1% | 79 | $4K | |
| 87081 | <1% | 416 | $4K | |
| 90715 | <1% | 220 | $4K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 205 | $4K |
| 87510 | <1% | 147 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,276 | $4K |
| 85007 | <1% | 1,028 | $3K | |
| 86038 | <1% | 262 | $3K | |
| 84520 | <1% | 539 | $3K | |
| J3490 | Unclassified drugs | <1% | 99 | $3K |
| 93971 | <1% | 99 | $3K | |
| 82274 | <1% | 182 | $3K | |
| 84550 | <1% | 1,160 | $3K | |
| 82247 | <1% | 353 | $3K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 3,723 | $3K |
| 82043 | <1% | 780 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,979 | $3K |
| 87902 | <1% | 14 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 454 | $3K |
| 80366 | <1% | 114 | $2K | |
| 87631 | <1% | 32 | $2K | |
| 71270 | <1% | 12 | $2K | |
| 71010 | <1% | 329 | $2K | |
| 84144 | <1% | 43 | $2K | |
| 93880 | <1% | 62 | $2K | |
| 82785 | <1% | 85 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 926 | $2K |
| J1738 | Injection, meloxicam, 1 mg | <1% | 228 | $2K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 816 | $2K |
| 84152 | <1% | 175 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 326 | $2K |
| 87641 | <1% | 105 | $2K | |
| A9270 | Non-covered item or service | <1% | 7,257 | $2K |
| 83615 | <1% | 360 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 712 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 127 | $2K |
| 83970 | <1% | 81 | $2K | |
| 83550 | <1% | 301 | $2K | |
| 87430 | <1% | 109 | $1K | |
| 83520 | <1% | 190 | $1K | |
| 82550 | <1% | 208 | $1K | |
| 85055 | <1% | 101 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 723 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,767 | $1K |
| 86920 | <1% | 24 | $1K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 31 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,906 | $1K |
| 80359 | <1% | 66 | $1K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 48 | $1K |
| 84436 | <1% | 195 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,397 | $1K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 543 | $1K |
| 80358 | <1% | 39 | $939.74 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 487 | $933.97 |
| 75571 | <1% | 28 | $898.66 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,644 | $897.93 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 81 | $881.16 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,177 | $879.56 |
| 86703 | <1% | 54 | $861.96 | |
| 0004A | <1% | 123 | $858.06 | |
| 82670 | <1% | 30 | $816.28 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 426 | $758.83 |
| 74019 | <1% | 37 | $737.37 | |
| 86200 | <1% | 103 | $724.48 | |
| 94729 | <1% | 34 | $718.36 | |
| 80347 | <1% | 27 | $691.38 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 23 | $675.00 |
| 72110 | <1% | 14 | $665.37 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,651 | $654.54 |
| 93975 | <1% | 15 | $593.18 | |
| 87467 | <1% | 42 | $589.43 | |
| 84480 | <1% | 43 | $568.50 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 16 | $551.32 |
| 86431 | <1% | 167 | $545.92 | |
| 96376 | <1% | 53 | $545.24 | |
| 77062 | <1% | 13 | $536.87 | |
| 94726 | <1% | 13 | $526.38 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 44 | $524.49 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 21 | $514.56 |
| G0378 | Hospital observation service, per hour | <1% | 442 | $481.00 |
| 86780 | <1% | 31 | $463.16 | |
| 90714 | <1% | 48 | $458.60 | |
| 73560 | <1% | 32 | $453.77 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $431.56 |
| 87205 | <1% | 87 | $381.15 | |
| 82105 | <1% | 31 | $380.84 | |
| 72070 | <1% | 25 | $354.50 | |
| 87420 | <1% | 27 | $334.62 | |
| 76870 | <1% | 24 | $316.80 | |
| 87045 | <1% | 27 | $311.85 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 945 | $289.87 |
| 84156 | <1% | 111 | $276.49 | |
| 84146 | <1% | 16 | $276.46 | |
| 83002 | <1% | 13 | $273.44 | |
| 83001 | <1% | 13 | $251.34 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 263 | $250.55 |
| 73080 | <1% | 12 | $234.42 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 174 | $226.35 |
| 87046 | <1% | 27 | $223.28 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 439 | $211.14 |
| 74000 | <1% | 13 | $210.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 215 | $167.65 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 30 | $166.06 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 152 | $164.77 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 57 | $158.59 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 99 | $152.44 |
| 82140 | <1% | 15 | $137.39 | |
| 86334 | <1% | 13 | $134.63 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 115 | $133.76 |
| 83721 | <1% | 41 | $113.25 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 151 | $106.52 |
| 82977 | <1% | 14 | $96.00 | |
| 82570 | <1% | 29 | $90.68 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 95 | $60.34 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 13 | $56.73 |
| 84165 | <1% | 14 | $51.42 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 197 | $48.74 |
| 81002 | <1% | 18 | $47.22 | |
| 36591 | <1% | 295 | $22.44 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 53 | $17.95 |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | <1% | 34 | $15.53 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 207 | $3.98 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 15 | $0.57 |
| 97598 | 0% | 17 | $0.00 | |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 13 | $0.00 |
| 99406 | 0% | 84 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 52 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENRY, DEBRA (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.